Tag: common shares

CALGARY, Alberta and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Magnetic North Acquisition Corp. (TSXV: MNC; MNC.PR.A) (“Magnetic North” or the “Company”) is providing this bi-weekly update on the status of the management cease trade order granted on May 9, 2025 (the “MCTO”) by its principal regulator, the Alberta Securities Commission (“ASC”) , under National Policy 12-203 - Management Cease Trade Orders (“NP 12-203”), following the Company’s announcement on May 8, 2025 (the “Default Announcement”) that it was unable to file its audited annual financial statements, ‎management’s discussion and analysis and related certifications for the year ended December ‎‎31, 2024 (the “Documents”) ‎on or before April 30, 2025, as required under applicable securities laws. The Company does not expect to file the Documents by the MCTO’s deadline of June 30, 2025. See (ii) below.

OKOTOKS, Alberta, June 20, 2025 (GLOBE NEWSWIRE) -- (TSX: MTL) The Board of Directors of Mullen Group Ltd. ("Mullen Group", "We", "Our" and/or the "Corporation") announced today that it has declared a monthly dividend of $0.07 per Common Share payable to the holders of record of Common Shares at the close of business on June 30, 2025. The dividend will be paid on July 15, 2025.

BEVERLY, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- ATN International, Inc. (Nasdaq: ATNI) announced that its Board of Directors has approved a quarterly dividend increase of 15% to $0.275 per share. The quarterly dividend will be payable on July 7, 2025, on all common shares outstanding to stockholders of record as of June 30, 2025.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

Update on Fixed Income Investor Meetings  

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH”) Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies¹, HTH is operated by the Advanced Regenerative Manufacturing Institute (“ARMI”) and its BioFabUSA initiative.